Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Evolocumab vs LDL Apheresis Evaluated

Atherosclerosis; 2017 Oct; Kawashiri, et al

In patients with heterozygous familial hypercholesterolemia (HeFH) withdrawing from regular apheresis, treatment with evolocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) when compared with LDL apheresis, a recent study found. 11 patients with HeFH undergoing biweekly LDL apheresis were switched to a biweekly subcutaneous injection of 140 mg of evolocumab. The primary endpoints were percent changes in mean LDL-C and apolipoprotein B (apoB) serum levels. Researchers found:

  • Evolocumab significantly reduced LDL-C by 62.5% compared with LDL apheresis.
  • apoB and serum lipoprotein (a) levels were also significantly reduced.
  • No adverse effects were observed other than a mild reduction in vitamin E serum levels.
  • Biweekly evolocumab injection therapy is less expensive and less time-consuming compared to biweekly LDL apheresis.

Kawashiri M, Nohara A, Higashikata T, et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis. 2017;265:225-230. doi:10.1016/j.atherosclerosis.2017.09.011.

This Week's Must Reads

AHA Guideline Says Meditation May Lower CV Risk, J Am Heart Assoc; ePub 2017 Sep 28; Levine, et al

Cognitive Decline in Patients with AF, Heart Rhythm; ePub 2017 Sep 21; Nishtala, et al

Risks of CV vs Non-CV Death After ACS, J Am Heart Assoc; ePub 2017 Sep 18; Fanaroff, et al

Hypertension Control Among US Young Adults, J Clin Hypertens; ePub 2017 Sep 19; King, et al

HeartWare HVAD System OK’d for Destination Therapy, Medtronic news release; 2017 Sep 27

Must Reads in Hypercholesterolemia

CV Safety of Evolocumab in Patients with Diabetes, Lancet Diabetes Endocrinol; ePub 2017 Sep 12; Sabatine, et al

Treatment Patterns of PCSK9 Inhibitors , Am J Cardiovasc Drugs; ePub 2017 Aug 28; Rane, et al

Evolocumab vs LDL Apheresis Evaluated, Atherosclerosis; 2017 Oct; Kawashiri, et al

High-Intensity Statin Therapy After Stroke, Stroke; ePub 2017 Sep 15; Kim, et al

Lipid Profiling of Children With FH, Atherosclerosis; ePub 2017 Sep 20; Christensen, et al